- Fondo di protezione
  Fondo di protezione di 1.000 BTC per salvaguardare i tuoi asset
- Carriera
  Unisciti a WEEX e costruisci il futuro
- Zona WXT
  Airdrop e commissioni esclusive
- Centro annunci
  Ricevi gli ultimi aggiornamenti da WEEX
- Trader d'élite
  Condividi le strategie e guadagna ricompense
- Crypto Wiki
  Padroneggia il trading con guide facili da seguire
- Affiliato
  Sblocca vantaggi esclusivi e provvigioni elevate
- Notizie crypto
  Rimani aggiornato con le ultime tendenze crypto
- Verificatore di contatti
  Verifica i canali che utilizzi
- Vantaggi VIP
  Diventa un VIP WEEX oggi stesso
- Calendario eventi
  Esplora gli eventi WEEX in tutto il mondo
Acquista crypto
- header.nav.buy
  header.nav.buy_desc
- Trading P2P
  Acquista criptovalute con 0 commissioni
Mercato
Futures
- Futures USDT-M
  Futures perpetui regolati in USDT
- Trading demo
  Demo futures USDT-M
- Informazioni sui futures
  Fai trading con fiducia
- Classifica
  Classifiche attuali e passate
Spot
Copy trading
WE-Launch

Scansiona per scaricare
Altre opzioni

US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB

By: theblockbeats.news|2025/07/28 12:12:26

BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.

The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.

Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.

Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.

Metaplanet raccoglierà $21 milioni tramite obbligazioni per acquistare altri Bitcoin

WEEX ruba la scena a BlockchainRIO 2025